Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Service is a strong player in the growing market of long-term care pharmacy services. Its technology-enabled services, partnerships with facilities and payors, and focus on improving clinical outcomes make it well-positioned for growth. The recent strong performance in the vaccine business, expected continued growth in 2026, and efficient integration of acquisitions are all sustainable drivers for future success. Therefore, Guardian Pharmacy Service's stock has a positive outlook.

Bears say

Guardian Pharmacy Service is facing significant regulatory risks and exposure to reimbursement mechanisms, as well as potential investigational risk due to the highly regulated healthcare industry. In addition, their acquisition strategy may not be successful in turning around acquired assets and blunting the impact of negative drug price negotiations. While the company operates in a promising market with potential for consolidation, their limited trading liquidity and potential for legal issues present concerns for their financial performance and potential stock value.

GRDN has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Strong Buy based on their latest research and market trends.

According to 5 analysts, GRDN has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.